Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-EVEREST: REGN7508 versus apixaban for stroke and systemic embolism prevention in atrial fibrillation
jRCT2031260365Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing REGN7508 + placebo with Apixaban + placebo (2 arms). Primary endpoints: Time to first occurrence of stroke or systemic embolism and Time to first ISTH major bleeding or ISTH clinically relevant non-major bleeding. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
REGN7508
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on jRCT2031260365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260365.